

19 July 2022

## ASX Announcement

### Dr Amy Patick joins Island's Scientific Advisory Board

- **Dr Amy Patick appointed to Island's Scientific Advisory Board**
- **Dr Patick is an accomplished virologist and pharmaceutical executive with over 30 years of Research and Development experience, including as former Chair of International Society for Antiviral Research**

MELBOURNE Australia, 19 July 2022: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") is pleased to advise that Dr Amy Patick has been appointed to its Scientific Advisory Board (SAB), effective immediately.

An accomplished virologist and pharmaceutical executive, Dr Patick has over 30 years of Research and Development experience within non-profit, start-up, and biotechnology organisations to large pharmaceutical companies.

While currently the President of Patick Pharmaceutical and Scientific Consulting, Dr Patick started her professional career as Research Investigator with Bristol-Myers Squibb and then joined Agouron Pharmaceuticals (which became Pfizer Global R&D), where she worked in various leadership positions leading up to her role as Head of Biology, Antiviral Therapeutic Area. In this capacity, Dr. Patick led the preclinical effort in the successful approval of Viracept (nelfinavir) for HIV infection. Later, she was Vice President, Biological Sciences at Genelabs Technologies; then Vice President of Research for Adamas Pharmaceuticals, then Acting CSO for Idekos. Dr Patick has had many years of involvement with the International Society for Antiviral Research, including as President.

Dr. Patick earned her PhD in Medical Microbiology from the University of Wisconsin, and had postdoctoral training at the Mayo Clinic/Foundation in Rochester, MN. She is the co-author of more than 80 scientific publications, more than 100 abstracts / presentations and is named on more than 10 patents.

*"I look forward to bringing my skills and experience to Island's Scientific Advisory Board to work on projects with the potential to save millions of lives. This role is a unique opportunity to advance Island's lead drug candidate, ISLA-101 for dengue fever and to evaluate the potential for future drugs in response to emerging viral infections," said Dr Amy Patick.*

Island's CEO, Dr David Foster commented, *"We are delighted to have a highly experienced virologist such as Dr Amy Patick join our SAB. Dr Patick brings a significant depth of scientific and leadership expertise to our SAB at a pivotal point on our drug repurposing pathway, and at a time when mosquito-borne diseases are spreading rapidly around the world. She is highly regarded for her experience conducting viral challenge trials which will be particularly valuable as we accelerate our clinical work over the coming months."*

In tandem with the appointment of Dr Amy Patick, Dr Simon Tucker will leave the SAB in order to focus on other roles. The Board extends its gratitude to Simon, whose extensive expertise in intellectual property led to advances in the Company's pharmaceutical research and development capabilities during his tenure.



On his departure, Dr. Tucker commented *"I have very much enjoyed working with Island and commend them on the selection of an exemplary SAB. The company is wholly committed to the development of drugs for the treatment of key viral diseases and is exceptionally well served by its strong management, Board and SAB. I expect and look forward to the successful outcome of the current portfolio projects."*

David Foster added: *"We are grateful for Simon's efforts at Island. He has made a vital contribution during his time on our Scientific Advisory Board and we wish him well in his future endeavours."*

Dr. Patick will be compensated as outlined in the Company prospectus for other SAB members with \$20,000 AUD annually, which can be paid at the Company's discretion in Company securities with a 20% increase in the value over the cash value.

**Approved for release to the ASX by:**

Dr Paul MacLeman  
Executive Chairman  
Island  
Pharmaceuticals Ltd  
[info@islandpharmaceuticals.com](mailto:info@islandpharmaceuticals.com)

Investors and media, for further information, please contact:

Jane Lowe  
IR Department Mobile: +61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

**About Island Pharmaceuticals**

---

Island (ASX: ILA) is a mid-clinical-stage drug repurposing company, focused on the topical area of antiviral therapeutics for infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue<sup>2</sup> fever and other mosquito (or vector) borne diseases. The Company is close to commencing a Phase 2a clinical trial in dengue-infected subjects.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

*Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.*

Visit [www.islandpharmaceuticals.com](http://www.islandpharmaceuticals.com) for more on Island.